nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—Protein Kinase Inhibitors—Vemurafenib—skin cancer	0.603	1	CiPCiCtD
Vandetanib—EGFR—Docetaxel—skin cancer	0.031	0.132	CbGbCtD
Vandetanib—ORM1—Vismodegib—skin cancer	0.031	0.132	CbGbCtD
Vandetanib—ORM1—Vemurafenib—skin cancer	0.0245	0.104	CbGbCtD
Vandetanib—ABCC1—Vemurafenib—skin cancer	0.0223	0.095	CbGbCtD
Vandetanib—ABCG2—Vismodegib—skin cancer	0.0189	0.0804	CbGbCtD
Vandetanib—ABCG2—Vemurafenib—skin cancer	0.0149	0.0635	CbGbCtD
Vandetanib—ABCC1—Dactinomycin—skin cancer	0.0148	0.0631	CbGbCtD
Vandetanib—ALB—Vismodegib—skin cancer	0.013	0.0554	CbGbCtD
Vandetanib—ALB—Vemurafenib—skin cancer	0.0103	0.0438	CbGbCtD
Vandetanib—ABCG2—Dactinomycin—skin cancer	0.00992	0.0422	CbGbCtD
Vandetanib—ABCC1—Docetaxel—skin cancer	0.00766	0.0326	CbGbCtD
Vandetanib—ABCG2—Fluorouracil—skin cancer	0.00671	0.0286	CbGbCtD
Vandetanib—CYP3A4—Imiquimod—skin cancer	0.00589	0.0251	CbGbCtD
Vandetanib—CYP3A4—Temozolomide—skin cancer	0.00589	0.0251	CbGbCtD
Vandetanib—ABCG2—Docetaxel—skin cancer	0.00512	0.0218	CbGbCtD
Vandetanib—ALB—Fluorouracil—skin cancer	0.00463	0.0197	CbGbCtD
Vandetanib—CYP3A4—Vismodegib—skin cancer	0.00408	0.0174	CbGbCtD
Vandetanib—CYP3A4—Vemurafenib—skin cancer	0.00323	0.0137	CbGbCtD
Vandetanib—PTK6—skin epidermis—skin cancer	0.00138	0.0294	CbGeAlD
Vandetanib—CYP3A4—Docetaxel—skin cancer	0.00111	0.00471	CbGbCtD
Vandetanib—PTK6—hair follicle—skin cancer	0.000987	0.021	CbGeAlD
Vandetanib—KDR—hindlimb—skin cancer	0.000761	0.0162	CbGeAlD
Vandetanib—PTK6—nipple—skin cancer	0.000669	0.0142	CbGeAlD
Vandetanib—KDR—appendage—skin cancer	0.000653	0.0139	CbGeAlD
Vandetanib—FLT4—endothelium—skin cancer	0.000599	0.0128	CbGeAlD
Vandetanib—RIPK2—endothelium—skin cancer	0.000596	0.0127	CbGeAlD
Vandetanib—ERBB3—hair follicle—skin cancer	0.000561	0.0119	CbGeAlD
Vandetanib—FLT4—blood vessel—skin cancer	0.000553	0.0118	CbGeAlD
Vandetanib—RIPK2—blood vessel—skin cancer	0.00055	0.0117	CbGeAlD
Vandetanib—MKNK1—hair follicle—skin cancer	0.000527	0.0112	CbGeAlD
Vandetanib—TEK—endothelium—skin cancer	0.000482	0.0103	CbGeAlD
Vandetanib—MAP4K5—hair follicle—skin cancer	0.000474	0.0101	CbGeAlD
Vandetanib—TEK—blood vessel—skin cancer	0.000445	0.00946	CbGeAlD
Vandetanib—YES1—hair follicle—skin cancer	0.000438	0.00932	CbGeAlD
Vandetanib—PTK6—skin of body—skin cancer	0.000428	0.00912	CbGeAlD
Vandetanib—SRC—endothelium—skin cancer	0.000428	0.00911	CbGeAlD
Vandetanib—SRC—blood vessel—skin cancer	0.000395	0.00841	CbGeAlD
Vandetanib—KDR—endothelium—skin cancer	0.000394	0.00838	CbGeAlD
Vandetanib—PTK6—mammalian vulva—skin cancer	0.000391	0.00831	CbGeAlD
Vandetanib—IRAK4—nipple—skin cancer	0.000388	0.00826	CbGeAlD
Vandetanib—TYRO3—connective tissue—skin cancer	0.000367	0.00781	CbGeAlD
Vandetanib—BLK—lymphoid tissue—skin cancer	0.000366	0.00779	CbGeAlD
Vandetanib—LYN—connective tissue—skin cancer	0.000365	0.00777	CbGeAlD
Vandetanib—KDR—blood vessel—skin cancer	0.000363	0.00773	CbGeAlD
Vandetanib—MKNK1—nipple—skin cancer	0.000357	0.0076	CbGeAlD
Vandetanib—LCK—nipple—skin cancer	0.000353	0.00751	CbGeAlD
Vandetanib—AXL—nipple—skin cancer	0.000351	0.00748	CbGeAlD
Vandetanib—RET—neck—skin cancer	0.000349	0.00743	CbGeAlD
Vandetanib—LTK—female reproductive system—skin cancer	0.000349	0.00743	CbGeAlD
Vandetanib—BMPR1B—epithelium—skin cancer	0.000341	0.00726	CbGeAlD
Vandetanib—SLK—nipple—skin cancer	0.000338	0.0072	CbGeAlD
Vandetanib—PTK6—female reproductive system—skin cancer	0.000335	0.00712	CbGeAlD
Vandetanib—TYRO3—skin of body—skin cancer	0.000331	0.00705	CbGeAlD
Vandetanib—FYN—nipple—skin cancer	0.000329	0.007	CbGeAlD
Vandetanib—MAP4K5—nipple—skin cancer	0.000321	0.00684	CbGeAlD
Vandetanib—PDGFRB—blood vessel—skin cancer	0.000315	0.00669	CbGeAlD
Vandetanib—FLT3—connective tissue—skin cancer	0.000312	0.00664	CbGeAlD
Vandetanib—EPHB6—nipple—skin cancer	0.000307	0.00654	CbGeAlD
Vandetanib—YES1—nipple—skin cancer	0.000297	0.00632	CbGeAlD
Vandetanib—LTK—head—skin cancer	0.000292	0.0062	CbGeAlD
Vandetanib—PLK4—lymphoid tissue—skin cancer	0.000286	0.00608	CbGeAlD
Vandetanib—RIPK2—connective tissue—skin cancer	0.000282	0.006	CbGeAlD
Vandetanib—EPHA8—head—skin cancer	0.00028	0.00595	CbGeAlD
Vandetanib—EPHA6—female reproductive system—skin cancer	0.000279	0.00594	CbGeAlD
Vandetanib—STK35—skin of body—skin cancer	0.000276	0.00587	CbGeAlD
Vandetanib—PLK4—female reproductive system—skin cancer	0.000276	0.00586	CbGeAlD
Vandetanib—ERBB3—connective tissue—skin cancer	0.00027	0.00574	CbGeAlD
Vandetanib—FLT4—epithelium—skin cancer	0.000269	0.00573	CbGeAlD
Vandetanib—TYRO3—lymphoid tissue—skin cancer	0.000268	0.00571	CbGeAlD
Vandetanib—RIPK2—epithelium—skin cancer	0.000268	0.0057	CbGeAlD
Vandetanib—LYN—lymphoid tissue—skin cancer	0.000267	0.00568	CbGeAlD
Vandetanib—MAP2K5—nipple—skin cancer	0.000263	0.00559	CbGeAlD
Vandetanib—KDR—nipple—skin cancer	0.000263	0.00559	CbGeAlD
Vandetanib—KDR—neck—skin cancer	0.00026	0.00553	CbGeAlD
Vandetanib—TYRO3—female reproductive system—skin cancer	0.000259	0.00551	CbGeAlD
Vandetanib—ERBB3—epithelium—skin cancer	0.000256	0.00545	CbGeAlD
Vandetanib—RIPK2—skin of body—skin cancer	0.000255	0.00542	CbGeAlD
Vandetanib—BMPR1B—female reproductive system—skin cancer	0.000254	0.0054	CbGeAlD
Vandetanib—MAP3K19—female reproductive system—skin cancer	0.000254	0.0054	CbGeAlD
Vandetanib—RET—connective tissue—skin cancer	0.00025	0.00533	CbGeAlD
Vandetanib—AXL—connective tissue—skin cancer	0.000249	0.0053	CbGeAlD
Vandetanib—ERBB3—skin of body—skin cancer	0.000244	0.00518	CbGeAlD
Vandetanib—EGFR—mammalian vulva—skin cancer	0.000239	0.0051	CbGeAlD
Vandetanib—RET—epithelium—skin cancer	0.000238	0.00506	CbGeAlD
Vandetanib—FYN—connective tissue—skin cancer	0.000233	0.00496	CbGeAlD
Vandetanib—EPHA6—head—skin cancer	0.000233	0.00496	CbGeAlD
Vandetanib—VEGFA—mammalian vulva—skin cancer	0.000232	0.00493	CbGeAlD
Vandetanib—FMO1—mammalian vulva—skin cancer	0.00023	0.0049	CbGeAlD
Vandetanib—FLT3—lymphoid tissue—skin cancer	0.000228	0.00486	CbGeAlD
Vandetanib—TEK—connective tissue—skin cancer	0.000228	0.00485	CbGeAlD
Vandetanib—ABCC1—hair follicle—skin cancer	0.000228	0.00484	CbGeAlD
Vandetanib—PDGFRB—nipple—skin cancer	0.000227	0.00484	CbGeAlD
Vandetanib—IRAK4—mammalian vulva—skin cancer	0.000227	0.00482	CbGeAlD
Vandetanib—AXL—skin of body—skin cancer	0.000225	0.00479	CbGeAlD
Vandetanib—PDGFRB—neck—skin cancer	0.000225	0.00479	CbGeAlD
Vandetanib—FLT3—female reproductive system—skin cancer	0.00022	0.00468	CbGeAlD
Vandetanib—TEK—epithelium—skin cancer	0.000216	0.00461	CbGeAlD
Vandetanib—TYRO3—head—skin cancer	0.000216	0.0046	CbGeAlD
Vandetanib—EPHA5—head—skin cancer	0.000216	0.0046	CbGeAlD
Vandetanib—STK35—female reproductive system—skin cancer	0.000216	0.00459	CbGeAlD
Vandetanib—LYN—head—skin cancer	0.000215	0.00458	CbGeAlD
Vandetanib—BMPR1B—head—skin cancer	0.000212	0.00451	CbGeAlD
Vandetanib—MAP3K19—head—skin cancer	0.000212	0.00451	CbGeAlD
Vandetanib—FYN—skin of body—skin cancer	0.000211	0.00448	CbGeAlD
Vandetanib—YES1—connective tissue—skin cancer	0.000211	0.00448	CbGeAlD
Vandetanib—MKNK1—mammalian vulva—skin cancer	0.000209	0.00444	CbGeAlD
Vandetanib—FLT4—lymphoid tissue—skin cancer	0.000207	0.00441	CbGeAlD
Vandetanib—BLK—lymph node—skin cancer	0.000206	0.00439	CbGeAlD
Vandetanib—LCK—mammalian vulva—skin cancer	0.000206	0.00439	CbGeAlD
Vandetanib—FGR—mammalian vulva—skin cancer	0.000206	0.00439	CbGeAlD
Vandetanib—AXL—mammalian vulva—skin cancer	0.000205	0.00437	CbGeAlD
Vandetanib—LTK—lymph node—skin cancer	0.000204	0.00434	CbGeAlD
Vandetanib—ABL1—nipple—skin cancer	0.000203	0.00431	CbGeAlD
Vandetanib—SRC—connective tissue—skin cancer	0.000203	0.00431	CbGeAlD
Vandetanib—IRAK4—lymphoid tissue—skin cancer	0.000201	0.00428	CbGeAlD
Vandetanib—FLT4—female reproductive system—skin cancer	0.0002	0.00425	CbGeAlD
Vandetanib—FMO3—mammalian vulva—skin cancer	0.000199	0.00424	CbGeAlD
Vandetanib—RIPK2—female reproductive system—skin cancer	0.000199	0.00423	CbGeAlD
Vandetanib—SLK—mammalian vulva—skin cancer	0.000198	0.0042	CbGeAlD
Vandetanib—ERBB3—lymphoid tissue—skin cancer	0.000197	0.0042	CbGeAlD
Vandetanib—EPHB6—skin of body—skin cancer	0.000197	0.00419	CbGeAlD
Vandetanib—SRC—epithelium—skin cancer	0.000192	0.00409	CbGeAlD
Vandetanib—FYN—mammalian vulva—skin cancer	0.000192	0.00409	CbGeAlD
Vandetanib—ERBB3—female reproductive system—skin cancer	0.00019	0.00405	CbGeAlD
Vandetanib—MAP4K5—mammalian vulva—skin cancer	0.000188	0.00399	CbGeAlD
Vandetanib—KDR—connective tissue—skin cancer	0.000186	0.00396	CbGeAlD
Vandetanib—MKNK1—lymphoid tissue—skin cancer	0.000185	0.00394	CbGeAlD
Vandetanib—FGR—lymphoid tissue—skin cancer	0.000183	0.00389	CbGeAlD
Vandetanib—RET—lymphoid tissue—skin cancer	0.000183	0.00389	CbGeAlD
Vandetanib—SRC—skin of body—skin cancer	0.000183	0.00389	CbGeAlD
Vandetanib—AXL—lymphoid tissue—skin cancer	0.000182	0.00388	CbGeAlD
Vandetanib—STK35—head—skin cancer	0.00018	0.00383	CbGeAlD
Vandetanib—EPHB6—mammalian vulva—skin cancer	0.000179	0.00382	CbGeAlD
Vandetanib—MKNK1—female reproductive system—skin cancer	0.000179	0.0038	CbGeAlD
Vandetanib—KDR—epithelium—skin cancer	0.000177	0.00376	CbGeAlD
Vandetanib—FGR—female reproductive system—skin cancer	0.000176	0.00376	CbGeAlD
Vandetanib—AXL—female reproductive system—skin cancer	0.000176	0.00374	CbGeAlD
Vandetanib—YES1—mammalian vulva—skin cancer	0.000173	0.00369	CbGeAlD
Vandetanib—STK10—mammalian vulva—skin cancer	0.000172	0.00366	CbGeAlD
Vandetanib—FYN—lymphoid tissue—skin cancer	0.000171	0.00363	CbGeAlD
Vandetanib—FLT4—head—skin cancer	0.000167	0.00355	CbGeAlD
Vandetanib—MAP4K5—lymphoid tissue—skin cancer	0.000167	0.00355	CbGeAlD
Vandetanib—TEK—lymphoid tissue—skin cancer	0.000167	0.00355	CbGeAlD
Vandetanib—RIPK2—head—skin cancer	0.000166	0.00353	CbGeAlD
Vandetanib—FMO1—head—skin cancer	0.000165	0.00351	CbGeAlD
Vandetanib—FYN—female reproductive system—skin cancer	0.000165	0.0035	CbGeAlD
Vandetanib—IRAK4—head—skin cancer	0.000162	0.00345	CbGeAlD
Vandetanib—PDGFRB—connective tissue—skin cancer	0.000161	0.00343	CbGeAlD
Vandetanib—PLK4—lymph node—skin cancer	0.000161	0.00343	CbGeAlD
Vandetanib—MAP4K5—female reproductive system—skin cancer	0.000161	0.00342	CbGeAlD
Vandetanib—TEK—female reproductive system—skin cancer	0.000161	0.00342	CbGeAlD
Vandetanib—ERBB3—head—skin cancer	0.000159	0.00338	CbGeAlD
Vandetanib—ABCC1—nipple—skin cancer	0.000154	0.00328	CbGeAlD
Vandetanib—YES1—lymphoid tissue—skin cancer	0.000154	0.00328	CbGeAlD
Vandetanib—MAP2K5—mammalian vulva—skin cancer	0.000153	0.00326	CbGeAlD
Vandetanib—KDR—mammalian vulva—skin cancer	0.000153	0.00326	CbGeAlD
Vandetanib—PDGFRB—epithelium—skin cancer	0.000153	0.00326	CbGeAlD
Vandetanib—STK10—lymphoid tissue—skin cancer	0.000153	0.00325	CbGeAlD
Vandetanib—MKNK1—head—skin cancer	0.000149	0.00318	CbGeAlD
Vandetanib—YES1—female reproductive system—skin cancer	0.000148	0.00316	CbGeAlD
Vandetanib—BMPR1B—lymph node—skin cancer	0.000148	0.00316	CbGeAlD
Vandetanib—SRC—lymphoid tissue—skin cancer	0.000148	0.00315	CbGeAlD
Vandetanib—FGR—head—skin cancer	0.000147	0.00314	CbGeAlD
Vandetanib—RET—head—skin cancer	0.000147	0.00314	CbGeAlD
Vandetanib—STK10—female reproductive system—skin cancer	0.000147	0.00313	CbGeAlD
Vandetanib—AXL—head—skin cancer	0.000147	0.00312	CbGeAlD
Vandetanib—PDGFRB—skin of body—skin cancer	0.000146	0.0031	CbGeAlD
Vandetanib—ABL1—connective tissue—skin cancer	0.000144	0.00306	CbGeAlD
Vandetanib—SRC—female reproductive system—skin cancer	0.000143	0.00304	CbGeAlD
Vandetanib—FMO3—head—skin cancer	0.000142	0.00303	CbGeAlD
Vandetanib—FYN—head—skin cancer	0.000137	0.00292	CbGeAlD
Vandetanib—KDR—lymphoid tissue—skin cancer	0.000136	0.0029	CbGeAlD
Vandetanib—TEK—head—skin cancer	0.000134	0.00286	CbGeAlD
Vandetanib—MAP4K5—head—skin cancer	0.000134	0.00286	CbGeAlD
Vandetanib—PDGFRB—mammalian vulva—skin cancer	0.000133	0.00283	CbGeAlD
Vandetanib—KDR—female reproductive system—skin cancer	0.000131	0.0028	CbGeAlD
Vandetanib—MAP2K5—female reproductive system—skin cancer	0.000131	0.0028	CbGeAlD
Vandetanib—ABL1—skin of body—skin cancer	0.00013	0.00276	CbGeAlD
Vandetanib—FLT3—lymph node—skin cancer	0.000129	0.00274	CbGeAlD
Vandetanib—EPHB6—head—skin cancer	0.000128	0.00273	CbGeAlD
Vandetanib—STK35—lymph node—skin cancer	0.000126	0.00268	CbGeAlD
Vandetanib—YES1—head—skin cancer	0.000124	0.00264	CbGeAlD
Vandetanib—ABL2—lymph node—skin cancer	0.000123	0.00262	CbGeAlD
Vandetanib—STK10—head—skin cancer	0.000123	0.00262	CbGeAlD
Vandetanib—EGFR—lymph node—skin cancer	0.00012	0.00255	CbGeAlD
Vandetanib—SRC—head—skin cancer	0.000119	0.00254	CbGeAlD
Vandetanib—ABL1—mammalian vulva—skin cancer	0.000118	0.00252	CbGeAlD
Vandetanib—PDGFRB—lymphoid tissue—skin cancer	0.000118	0.00251	CbGeAlD
Vandetanib—FLT4—lymph node—skin cancer	0.000117	0.00249	CbGeAlD
Vandetanib—RIPK2—lymph node—skin cancer	0.000116	0.00247	CbGeAlD
Vandetanib—VEGFA—lymph node—skin cancer	0.000116	0.00247	CbGeAlD
Vandetanib—FMO1—lymph node—skin cancer	0.000115	0.00245	CbGeAlD
Vandetanib—PDGFRB—female reproductive system—skin cancer	0.000114	0.00242	CbGeAlD
Vandetanib—IRAK4—lymph node—skin cancer	0.000114	0.00242	CbGeAlD
Vandetanib—ERBB3—lymph node—skin cancer	0.000111	0.00237	CbGeAlD
Vandetanib—MAP2K5—head—skin cancer	0.00011	0.00234	CbGeAlD
Vandetanib—KDR—head—skin cancer	0.00011	0.00234	CbGeAlD
Vandetanib—Haemorrhage—Bleomycin—skin cancer	0.000107	0.00178	CcSEcCtD
Vandetanib—ORM1—female reproductive system—skin cancer	0.000107	0.00227	CbGeAlD
Vandetanib—Infection—Imiquimod—skin cancer	0.000106	0.00177	CcSEcCtD
Vandetanib—Neutropenia—Temozolomide—skin cancer	0.000105	0.00175	CcSEcCtD
Vandetanib—Dysuria—Temozolomide—skin cancer	0.000105	0.00175	CcSEcCtD
Vandetanib—ABL1—lymphoid tissue—skin cancer	0.000105	0.00224	CbGeAlD
Vandetanib—Nervous system disorder—Imiquimod—skin cancer	0.000105	0.00174	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Temozolomide—skin cancer	0.000105	0.00174	CcSEcCtD
Vandetanib—MKNK1—lymph node—skin cancer	0.000105	0.00222	CbGeAlD
Vandetanib—Pollakiuria—Temozolomide—skin cancer	0.000104	0.00173	CcSEcCtD
Vandetanib—Skin disorder—Imiquimod—skin cancer	0.000104	0.00173	CcSEcCtD
Vandetanib—Dysphagia—Fluorouracil—skin cancer	0.000104	0.00173	CcSEcCtD
Vandetanib—Sepsis—Docetaxel—skin cancer	0.000104	0.00172	CcSEcCtD
Vandetanib—RET—lymph node—skin cancer	0.000103	0.0022	CbGeAlD
Vandetanib—FGR—lymph node—skin cancer	0.000103	0.0022	CbGeAlD
Vandetanib—LCK—lymph node—skin cancer	0.000103	0.0022	CbGeAlD
Vandetanib—AXL—lymph node—skin cancer	0.000103	0.00219	CbGeAlD
Vandetanib—Photosensitivity reaction—Temozolomide—skin cancer	0.000103	0.00171	CcSEcCtD
Vandetanib—Weight decreased—Temozolomide—skin cancer	0.000102	0.0017	CcSEcCtD
Vandetanib—Hyperglycaemia—Temozolomide—skin cancer	0.000102	0.00169	CcSEcCtD
Vandetanib—ABL1—female reproductive system—skin cancer	0.000101	0.00216	CbGeAlD
Vandetanib—Pneumonia—Temozolomide—skin cancer	0.000101	0.00168	CcSEcCtD
Vandetanib—Infestation—Temozolomide—skin cancer	0.0001	0.00167	CcSEcCtD
Vandetanib—Infestation NOS—Temozolomide—skin cancer	0.0001	0.00167	CcSEcCtD
Vandetanib—Depression—Temozolomide—skin cancer	0.0001	0.00167	CcSEcCtD
Vandetanib—FMO3—lymph node—skin cancer	9.97e-05	0.00212	CbGeAlD
Vandetanib—Stevens-Johnson syndrome—Temozolomide—skin cancer	9.95e-05	0.00166	CcSEcCtD
Vandetanib—SLK—lymph node—skin cancer	9.9e-05	0.00211	CbGeAlD
Vandetanib—Body temperature increased—Vemurafenib—skin cancer	9.9e-05	0.00165	CcSEcCtD
Vandetanib—Stomatitis—Temozolomide—skin cancer	9.78e-05	0.00163	CcSEcCtD
Vandetanib—Urinary tract infection—Temozolomide—skin cancer	9.75e-05	0.00162	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Imiquimod—skin cancer	9.73e-05	0.00162	CcSEcCtD
Vandetanib—Insomnia—Imiquimod—skin cancer	9.66e-05	0.00161	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Fluorouracil—skin cancer	9.64e-05	0.00161	CcSEcCtD
Vandetanib—FYN—lymph node—skin cancer	9.62e-05	0.00205	CbGeAlD
Vandetanib—Paraesthesia—Imiquimod—skin cancer	9.59e-05	0.0016	CcSEcCtD
Vandetanib—Dyspnoea—Imiquimod—skin cancer	9.52e-05	0.00159	CcSEcCtD
Vandetanib—PDGFRB—head—skin cancer	9.5e-05	0.00202	CbGeAlD
Vandetanib—Hepatobiliary disease—Temozolomide—skin cancer	9.49e-05	0.00158	CcSEcCtD
Vandetanib—Photosensitivity reaction—Fluorouracil—skin cancer	9.46e-05	0.00158	CcSEcCtD
Vandetanib—Alopecia—Bleomycin—skin cancer	9.44e-05	0.00157	CcSEcCtD
Vandetanib—Erythema multiforme—Dactinomycin—skin cancer	9.42e-05	0.00157	CcSEcCtD
Vandetanib—Sinusitis—Temozolomide—skin cancer	9.41e-05	0.00157	CcSEcCtD
Vandetanib—MAP4K5—lymph node—skin cancer	9.4e-05	0.002	CbGeAlD
Vandetanib—TEK—lymph node—skin cancer	9.4e-05	0.002	CbGeAlD
Vandetanib—Dyspepsia—Imiquimod—skin cancer	9.4e-05	0.00157	CcSEcCtD
Vandetanib—Pneumonia—Fluorouracil—skin cancer	9.3e-05	0.00155	CcSEcCtD
Vandetanib—Decreased appetite—Imiquimod—skin cancer	9.28e-05	0.00155	CcSEcCtD
Vandetanib—Infestation—Fluorouracil—skin cancer	9.24e-05	0.00154	CcSEcCtD
Vandetanib—Infestation NOS—Fluorouracil—skin cancer	9.24e-05	0.00154	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Imiquimod—skin cancer	9.22e-05	0.00154	CcSEcCtD
Vandetanib—Fatigue—Imiquimod—skin cancer	9.21e-05	0.00153	CcSEcCtD
Vandetanib—Atrial fibrillation—Docetaxel—skin cancer	9.14e-05	0.00152	CcSEcCtD
Vandetanib—Pain—Imiquimod—skin cancer	9.13e-05	0.00152	CcSEcCtD
Vandetanib—Dermatitis bullous—Docetaxel—skin cancer	9.06e-05	0.00151	CcSEcCtD
Vandetanib—Haemoglobin—Temozolomide—skin cancer	9.05e-05	0.00151	CcSEcCtD
Vandetanib—ABCC1—mammalian vulva—skin cancer	9.02e-05	0.00192	CbGeAlD
Vandetanib—Stomatitis—Fluorouracil—skin cancer	9.01e-05	0.0015	CcSEcCtD
Vandetanib—Haemorrhage—Temozolomide—skin cancer	9.01e-05	0.0015	CcSEcCtD
Vandetanib—EPHB6—lymph node—skin cancer	8.99e-05	0.00191	CbGeAlD
Vandetanib—Conjunctivitis—Fluorouracil—skin cancer	8.99e-05	0.0015	CcSEcCtD
Vandetanib—Urinary tract infection—Fluorouracil—skin cancer	8.99e-05	0.0015	CcSEcCtD
Vandetanib—Asthenia—Vemurafenib—skin cancer	8.98e-05	0.0015	CcSEcCtD
Vandetanib—Urinary tract disorder—Temozolomide—skin cancer	8.89e-05	0.00148	CcSEcCtD
Vandetanib—Cardiac failure—Docetaxel—skin cancer	8.87e-05	0.00148	CcSEcCtD
Vandetanib—Pruritus—Vemurafenib—skin cancer	8.86e-05	0.00148	CcSEcCtD
Vandetanib—Lethargy—Docetaxel—skin cancer	8.84e-05	0.00147	CcSEcCtD
Vandetanib—Urethral disorder—Temozolomide—skin cancer	8.83e-05	0.00147	CcSEcCtD
Vandetanib—Alopecia—Dactinomycin—skin cancer	8.8e-05	0.00147	CcSEcCtD
Vandetanib—Gastrointestinal pain—Imiquimod—skin cancer	8.73e-05	0.00145	CcSEcCtD
Vandetanib—Epistaxis—Fluorouracil—skin cancer	8.72e-05	0.00145	CcSEcCtD
Vandetanib—Hyponatraemia—Docetaxel—skin cancer	8.69e-05	0.00145	CcSEcCtD
Vandetanib—YES1—lymph node—skin cancer	8.69e-05	0.00185	CbGeAlD
Vandetanib—Visual impairment—Temozolomide—skin cancer	8.68e-05	0.00145	CcSEcCtD
Vandetanib—Sinusitis—Fluorouracil—skin cancer	8.67e-05	0.00145	CcSEcCtD
Vandetanib—Gastrointestinal haemorrhage—Docetaxel—skin cancer	8.66e-05	0.00144	CcSEcCtD
Vandetanib—STK10—lymph node—skin cancer	8.61e-05	0.00183	CbGeAlD
Vandetanib—Diarrhoea—Vemurafenib—skin cancer	8.57e-05	0.00143	CcSEcCtD
Vandetanib—Erythema multiforme—Temozolomide—skin cancer	8.52e-05	0.00142	CcSEcCtD
Vandetanib—ABL1—head—skin cancer	8.47e-05	0.0018	CbGeAlD
Vandetanib—Body temperature increased—Imiquimod—skin cancer	8.44e-05	0.00141	CcSEcCtD
Vandetanib—Abdominal pain—Imiquimod—skin cancer	8.44e-05	0.00141	CcSEcCtD
Vandetanib—Eye disorder—Temozolomide—skin cancer	8.42e-05	0.0014	CcSEcCtD
Vandetanib—Cardiac disorder—Temozolomide—skin cancer	8.36e-05	0.00139	CcSEcCtD
Vandetanib—SRC—lymph node—skin cancer	8.36e-05	0.00178	CbGeAlD
Vandetanib—Haemoglobin—Fluorouracil—skin cancer	8.34e-05	0.00139	CcSEcCtD
Vandetanib—Haemorrhage—Fluorouracil—skin cancer	8.3e-05	0.00138	CcSEcCtD
Vandetanib—Dizziness—Vemurafenib—skin cancer	8.28e-05	0.00138	CcSEcCtD
Vandetanib—Angiopathy—Temozolomide—skin cancer	8.17e-05	0.00136	CcSEcCtD
Vandetanib—Mediastinal disorder—Temozolomide—skin cancer	8.12e-05	0.00135	CcSEcCtD
Vandetanib—Cough—Bleomycin—skin cancer	8.11e-05	0.00135	CcSEcCtD
Vandetanib—Dehydration—Docetaxel—skin cancer	8.05e-05	0.00134	CcSEcCtD
Vandetanib—Vomiting—Vemurafenib—skin cancer	7.96e-05	0.00133	CcSEcCtD
Vandetanib—Alopecia—Temozolomide—skin cancer	7.96e-05	0.00133	CcSEcCtD
Vandetanib—Dry skin—Docetaxel—skin cancer	7.94e-05	0.00132	CcSEcCtD
Vandetanib—Chest pain—Bleomycin—skin cancer	7.91e-05	0.00132	CcSEcCtD
Vandetanib—Rash—Vemurafenib—skin cancer	7.89e-05	0.00132	CcSEcCtD
Vandetanib—Mental disorder—Temozolomide—skin cancer	7.89e-05	0.00131	CcSEcCtD
Vandetanib—Dermatitis—Vemurafenib—skin cancer	7.89e-05	0.00131	CcSEcCtD
Vandetanib—Headache—Vemurafenib—skin cancer	7.84e-05	0.00131	CcSEcCtD
Vandetanib—Malnutrition—Temozolomide—skin cancer	7.84e-05	0.00131	CcSEcCtD
Vandetanib—Nasopharyngitis—Docetaxel—skin cancer	7.74e-05	0.00129	CcSEcCtD
Vandetanib—MAP2K5—lymph node—skin cancer	7.69e-05	0.00164	CbGeAlD
Vandetanib—KDR—lymph node—skin cancer	7.69e-05	0.00164	CbGeAlD
Vandetanib—Dysgeusia—Temozolomide—skin cancer	7.68e-05	0.00128	CcSEcCtD
Vandetanib—Asthenia—Imiquimod—skin cancer	7.66e-05	0.00128	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Docetaxel—skin cancer	7.64e-05	0.00127	CcSEcCtD
Vandetanib—Oedema—Bleomycin—skin cancer	7.59e-05	0.00126	CcSEcCtD
Vandetanib—Pruritus—Imiquimod—skin cancer	7.55e-05	0.00126	CcSEcCtD
Vandetanib—Infection—Bleomycin—skin cancer	7.54e-05	0.00126	CcSEcCtD
Vandetanib—Dysphagia—Docetaxel—skin cancer	7.48e-05	0.00125	CcSEcCtD
Vandetanib—ABCG2—mammalian vulva—skin cancer	7.46e-05	0.00159	CbGeAlD
Vandetanib—Nausea—Vemurafenib—skin cancer	7.44e-05	0.00124	CcSEcCtD
Vandetanib—Thrombocytopenia—Bleomycin—skin cancer	7.43e-05	0.00124	CcSEcCtD
Vandetanib—Arrhythmia—Fluorouracil—skin cancer	7.41e-05	0.00124	CcSEcCtD
Vandetanib—Vision blurred—Temozolomide—skin cancer	7.39e-05	0.00123	CcSEcCtD
Vandetanib—Bronchospasm—Docetaxel—skin cancer	7.36e-05	0.00123	CcSEcCtD
Vandetanib—Tremor—Temozolomide—skin cancer	7.35e-05	0.00122	CcSEcCtD
Vandetanib—Alopecia—Fluorouracil—skin cancer	7.33e-05	0.00122	CcSEcCtD
Vandetanib—Diarrhoea—Imiquimod—skin cancer	7.31e-05	0.00122	CcSEcCtD
Vandetanib—Oedema—Dactinomycin—skin cancer	7.07e-05	0.00118	CcSEcCtD
Vandetanib—Dizziness—Imiquimod—skin cancer	7.06e-05	0.00118	CcSEcCtD
Vandetanib—Infection—Dactinomycin—skin cancer	7.03e-05	0.00117	CcSEcCtD
Vandetanib—Neutropenia—Docetaxel—skin cancer	7e-05	0.00117	CcSEcCtD
Vandetanib—Thrombocytopenia—Dactinomycin—skin cancer	6.93e-05	0.00115	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Bleomycin—skin cancer	6.91e-05	0.00115	CcSEcCtD
Vandetanib—Cough—Temozolomide—skin cancer	6.84e-05	0.00114	CcSEcCtD
Vandetanib—Paraesthesia—Bleomycin—skin cancer	6.81e-05	0.00113	CcSEcCtD
Vandetanib—Vision blurred—Fluorouracil—skin cancer	6.81e-05	0.00113	CcSEcCtD
Vandetanib—Convulsion—Temozolomide—skin cancer	6.79e-05	0.00113	CcSEcCtD
Vandetanib—Vomiting—Imiquimod—skin cancer	6.79e-05	0.00113	CcSEcCtD
Vandetanib—Weight decreased—Docetaxel—skin cancer	6.77e-05	0.00113	CcSEcCtD
Vandetanib—Hypertension—Temozolomide—skin cancer	6.77e-05	0.00113	CcSEcCtD
Vandetanib—Dyspnoea—Bleomycin—skin cancer	6.76e-05	0.00113	CcSEcCtD
Vandetanib—Rash—Imiquimod—skin cancer	6.73e-05	0.00112	CcSEcCtD
Vandetanib—Dermatitis—Imiquimod—skin cancer	6.73e-05	0.00112	CcSEcCtD
Vandetanib—Pneumonia—Docetaxel—skin cancer	6.71e-05	0.00112	CcSEcCtD
Vandetanib—Headache—Imiquimod—skin cancer	6.69e-05	0.00111	CcSEcCtD
Vandetanib—Arthralgia—Temozolomide—skin cancer	6.68e-05	0.00111	CcSEcCtD
Vandetanib—Infestation NOS—Docetaxel—skin cancer	6.67e-05	0.00111	CcSEcCtD
Vandetanib—Infestation—Docetaxel—skin cancer	6.67e-05	0.00111	CcSEcCtD
Vandetanib—PDGFRB—lymph node—skin cancer	6.65e-05	0.00142	CbGeAlD
Vandetanib—Anxiety—Temozolomide—skin cancer	6.65e-05	0.00111	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	6.63e-05	0.0011	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Docetaxel—skin cancer	6.61e-05	0.0011	CcSEcCtD
Vandetanib—Decreased appetite—Bleomycin—skin cancer	6.59e-05	0.0011	CcSEcCtD
Vandetanib—Renal failure—Docetaxel—skin cancer	6.56e-05	0.00109	CcSEcCtD
Vandetanib—Dry mouth—Temozolomide—skin cancer	6.53e-05	0.00109	CcSEcCtD
Vandetanib—Stomatitis—Docetaxel—skin cancer	6.5e-05	0.00108	CcSEcCtD
Vandetanib—Pain—Bleomycin—skin cancer	6.49e-05	0.00108	CcSEcCtD
Vandetanib—Conjunctivitis—Docetaxel—skin cancer	6.49e-05	0.00108	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Dactinomycin—skin cancer	6.45e-05	0.00107	CcSEcCtD
Vandetanib—Oedema—Temozolomide—skin cancer	6.4e-05	0.00107	CcSEcCtD
Vandetanib—Infection—Temozolomide—skin cancer	6.36e-05	0.00106	CcSEcCtD
Vandetanib—Nausea—Imiquimod—skin cancer	6.34e-05	0.00106	CcSEcCtD
Vandetanib—Hepatobiliary disease—Docetaxel—skin cancer	6.31e-05	0.00105	CcSEcCtD
Vandetanib—Epistaxis—Docetaxel—skin cancer	6.29e-05	0.00105	CcSEcCtD
Vandetanib—Nervous system disorder—Temozolomide—skin cancer	6.28e-05	0.00105	CcSEcCtD
Vandetanib—Thrombocytopenia—Temozolomide—skin cancer	6.27e-05	0.00104	CcSEcCtD
Vandetanib—Convulsion—Fluorouracil—skin cancer	6.26e-05	0.00104	CcSEcCtD
Vandetanib—ORM1—lymph node—skin cancer	6.24e-05	0.00133	CbGeAlD
Vandetanib—Skin disorder—Temozolomide—skin cancer	6.22e-05	0.00104	CcSEcCtD
Vandetanib—Chest pain—Fluorouracil—skin cancer	6.15e-05	0.00102	CcSEcCtD
Vandetanib—Decreased appetite—Dactinomycin—skin cancer	6.15e-05	0.00102	CcSEcCtD
Vandetanib—Fatigue—Dactinomycin—skin cancer	6.1e-05	0.00102	CcSEcCtD
Vandetanib—Pain—Dactinomycin—skin cancer	6.05e-05	0.00101	CcSEcCtD
Vandetanib—Haemoglobin—Docetaxel—skin cancer	6.02e-05	0.001	CcSEcCtD
Vandetanib—Body temperature increased—Bleomycin—skin cancer	6e-05	0.000999	CcSEcCtD
Vandetanib—Haemorrhage—Docetaxel—skin cancer	5.99e-05	0.000998	CcSEcCtD
Vandetanib—ABL1—lymph node—skin cancer	5.93e-05	0.00126	CbGeAlD
Vandetanib—Urinary tract disorder—Docetaxel—skin cancer	5.92e-05	0.000986	CcSEcCtD
Vandetanib—Oedema—Fluorouracil—skin cancer	5.9e-05	0.000982	CcSEcCtD
Vandetanib—Urethral disorder—Docetaxel—skin cancer	5.87e-05	0.000978	CcSEcCtD
Vandetanib—Infection—Fluorouracil—skin cancer	5.86e-05	0.000976	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Temozolomide—skin cancer	5.83e-05	0.000971	CcSEcCtD
Vandetanib—Insomnia—Temozolomide—skin cancer	5.79e-05	0.000964	CcSEcCtD
Vandetanib—Gastrointestinal pain—Dactinomycin—skin cancer	5.79e-05	0.000964	CcSEcCtD
Vandetanib—Nervous system disorder—Fluorouracil—skin cancer	5.78e-05	0.000963	CcSEcCtD
Vandetanib—Thrombocytopenia—Fluorouracil—skin cancer	5.77e-05	0.000962	CcSEcCtD
Vandetanib—Visual impairment—Docetaxel—skin cancer	5.77e-05	0.000962	CcSEcCtD
Vandetanib—Paraesthesia—Temozolomide—skin cancer	5.75e-05	0.000957	CcSEcCtD
Vandetanib—Dyspnoea—Temozolomide—skin cancer	5.7e-05	0.000951	CcSEcCtD
Vandetanib—Erythema multiforme—Docetaxel—skin cancer	5.66e-05	0.000944	CcSEcCtD
Vandetanib—Dyspepsia—Temozolomide—skin cancer	5.63e-05	0.000939	CcSEcCtD
Vandetanib—Eye disorder—Docetaxel—skin cancer	5.6e-05	0.000933	CcSEcCtD
Vandetanib—Body temperature increased—Dactinomycin—skin cancer	5.59e-05	0.000932	CcSEcCtD
Vandetanib—Abdominal pain—Dactinomycin—skin cancer	5.59e-05	0.000932	CcSEcCtD
Vandetanib—Decreased appetite—Temozolomide—skin cancer	5.56e-05	0.000927	CcSEcCtD
Vandetanib—Cardiac disorder—Docetaxel—skin cancer	5.56e-05	0.000926	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Temozolomide—skin cancer	5.52e-05	0.00092	CcSEcCtD
Vandetanib—Fatigue—Temozolomide—skin cancer	5.52e-05	0.000919	CcSEcCtD
Vandetanib—ALB—lymph node—skin cancer	5.47e-05	0.00116	CbGeAlD
Vandetanib—Pain—Temozolomide—skin cancer	5.47e-05	0.000912	CcSEcCtD
Vandetanib—Constipation—Temozolomide—skin cancer	5.47e-05	0.000912	CcSEcCtD
Vandetanib—Asthenia—Bleomycin—skin cancer	5.44e-05	0.000907	CcSEcCtD
Vandetanib—Angiopathy—Docetaxel—skin cancer	5.43e-05	0.000905	CcSEcCtD
Vandetanib—Mediastinal disorder—Docetaxel—skin cancer	5.4e-05	0.000899	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Fluorouracil—skin cancer	5.37e-05	0.000895	CcSEcCtD
Vandetanib—Pruritus—Bleomycin—skin cancer	5.37e-05	0.000894	CcSEcCtD
Vandetanib—Arrhythmia—Docetaxel—skin cancer	5.35e-05	0.000892	CcSEcCtD
Vandetanib—Insomnia—Fluorouracil—skin cancer	5.33e-05	0.000888	CcSEcCtD
Vandetanib—Paraesthesia—Fluorouracil—skin cancer	5.29e-05	0.000882	CcSEcCtD
Vandetanib—Alopecia—Docetaxel—skin cancer	5.29e-05	0.000882	CcSEcCtD
Vandetanib—Dyspnoea—Fluorouracil—skin cancer	5.26e-05	0.000876	CcSEcCtD
Vandetanib—Mental disorder—Docetaxel—skin cancer	5.25e-05	0.000874	CcSEcCtD
Vandetanib—Gastrointestinal pain—Temozolomide—skin cancer	5.23e-05	0.000872	CcSEcCtD
Vandetanib—Malnutrition—Docetaxel—skin cancer	5.21e-05	0.000869	CcSEcCtD
Vandetanib—Dyspepsia—Fluorouracil—skin cancer	5.19e-05	0.000865	CcSEcCtD
Vandetanib—Decreased appetite—Fluorouracil—skin cancer	5.13e-05	0.000854	CcSEcCtD
Vandetanib—Dysgeusia—Docetaxel—skin cancer	5.11e-05	0.000851	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Fluorouracil—skin cancer	5.09e-05	0.000848	CcSEcCtD
Vandetanib—Asthenia—Dactinomycin—skin cancer	5.08e-05	0.000846	CcSEcCtD
Vandetanib—Abdominal pain—Temozolomide—skin cancer	5.06e-05	0.000843	CcSEcCtD
Vandetanib—Body temperature increased—Temozolomide—skin cancer	5.06e-05	0.000843	CcSEcCtD
Vandetanib—Pain—Fluorouracil—skin cancer	5.04e-05	0.00084	CcSEcCtD
Vandetanib—Muscle spasms—Docetaxel—skin cancer	5.01e-05	0.000835	CcSEcCtD
Vandetanib—Diarrhoea—Dactinomycin—skin cancer	4.84e-05	0.000807	CcSEcCtD
Vandetanib—Vomiting—Bleomycin—skin cancer	4.82e-05	0.000804	CcSEcCtD
Vandetanib—Rash—Bleomycin—skin cancer	4.78e-05	0.000797	CcSEcCtD
Vandetanib—Dermatitis—Bleomycin—skin cancer	4.78e-05	0.000796	CcSEcCtD
Vandetanib—Body temperature increased—Fluorouracil—skin cancer	4.66e-05	0.000777	CcSEcCtD
Vandetanib—Asthenia—Temozolomide—skin cancer	4.59e-05	0.000765	CcSEcCtD
Vandetanib—Loss of consciousness—Docetaxel—skin cancer	4.58e-05	0.000764	CcSEcCtD
Vandetanib—Cough—Docetaxel—skin cancer	4.55e-05	0.000758	CcSEcCtD
Vandetanib—Pruritus—Temozolomide—skin cancer	4.53e-05	0.000754	CcSEcCtD
Vandetanib—Convulsion—Docetaxel—skin cancer	4.52e-05	0.000753	CcSEcCtD
Vandetanib—ABCC1—lymph node—skin cancer	4.52e-05	0.000961	CbGeAlD
Vandetanib—Nausea—Bleomycin—skin cancer	4.51e-05	0.000751	CcSEcCtD
Vandetanib—Hypertension—Docetaxel—skin cancer	4.5e-05	0.00075	CcSEcCtD
Vandetanib—Vomiting—Dactinomycin—skin cancer	4.5e-05	0.000749	CcSEcCtD
Vandetanib—Rash—Dactinomycin—skin cancer	4.46e-05	0.000743	CcSEcCtD
Vandetanib—CYP3A4—female reproductive system—skin cancer	4.45e-05	0.000948	CbGeAlD
Vandetanib—Arthralgia—Docetaxel—skin cancer	4.44e-05	0.00074	CcSEcCtD
Vandetanib—Chest pain—Docetaxel—skin cancer	4.44e-05	0.00074	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	4.41e-05	0.000735	CcSEcCtD
Vandetanib—Diarrhoea—Temozolomide—skin cancer	4.38e-05	0.000729	CcSEcCtD
Vandetanib—Dry mouth—Docetaxel—skin cancer	4.34e-05	0.000723	CcSEcCtD
Vandetanib—Oedema—Docetaxel—skin cancer	4.26e-05	0.000709	CcSEcCtD
Vandetanib—Dizziness—Temozolomide—skin cancer	4.23e-05	0.000705	CcSEcCtD
Vandetanib—Infection—Docetaxel—skin cancer	4.23e-05	0.000704	CcSEcCtD
Vandetanib—Nausea—Dactinomycin—skin cancer	4.2e-05	0.0007	CcSEcCtD
Vandetanib—Nervous system disorder—Docetaxel—skin cancer	4.17e-05	0.000695	CcSEcCtD
Vandetanib—Pruritus—Fluorouracil—skin cancer	4.17e-05	0.000695	CcSEcCtD
Vandetanib—Thrombocytopenia—Docetaxel—skin cancer	4.17e-05	0.000694	CcSEcCtD
Vandetanib—Skin disorder—Docetaxel—skin cancer	4.13e-05	0.000689	CcSEcCtD
Vandetanib—Vomiting—Temozolomide—skin cancer	4.07e-05	0.000678	CcSEcCtD
Vandetanib—Rash—Temozolomide—skin cancer	4.03e-05	0.000672	CcSEcCtD
Vandetanib—Diarrhoea—Fluorouracil—skin cancer	4.03e-05	0.000672	CcSEcCtD
Vandetanib—Dermatitis—Temozolomide—skin cancer	4.03e-05	0.000672	CcSEcCtD
Vandetanib—Headache—Temozolomide—skin cancer	4.01e-05	0.000668	CcSEcCtD
Vandetanib—Dizziness—Fluorouracil—skin cancer	3.9e-05	0.00065	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Docetaxel—skin cancer	3.88e-05	0.000646	CcSEcCtD
Vandetanib—Insomnia—Docetaxel—skin cancer	3.85e-05	0.000641	CcSEcCtD
Vandetanib—Paraesthesia—Docetaxel—skin cancer	3.82e-05	0.000637	CcSEcCtD
Vandetanib—Nausea—Temozolomide—skin cancer	3.8e-05	0.000633	CcSEcCtD
Vandetanib—Dyspnoea—Docetaxel—skin cancer	3.79e-05	0.000632	CcSEcCtD
Vandetanib—Vomiting—Fluorouracil—skin cancer	3.75e-05	0.000625	CcSEcCtD
Vandetanib—Dyspepsia—Docetaxel—skin cancer	3.75e-05	0.000624	CcSEcCtD
Vandetanib—ABCG2—lymph node—skin cancer	3.74e-05	0.000796	CbGeAlD
Vandetanib—Rash—Fluorouracil—skin cancer	3.72e-05	0.000619	CcSEcCtD
Vandetanib—Dermatitis—Fluorouracil—skin cancer	3.71e-05	0.000619	CcSEcCtD
Vandetanib—Decreased appetite—Docetaxel—skin cancer	3.7e-05	0.000616	CcSEcCtD
Vandetanib—Headache—Fluorouracil—skin cancer	3.69e-05	0.000615	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Docetaxel—skin cancer	3.67e-05	0.000612	CcSEcCtD
Vandetanib—Fatigue—Docetaxel—skin cancer	3.67e-05	0.000611	CcSEcCtD
Vandetanib—Pain—Docetaxel—skin cancer	3.64e-05	0.000606	CcSEcCtD
Vandetanib—Constipation—Docetaxel—skin cancer	3.64e-05	0.000606	CcSEcCtD
Vandetanib—Nausea—Fluorouracil—skin cancer	3.5e-05	0.000584	CcSEcCtD
Vandetanib—Gastrointestinal pain—Docetaxel—skin cancer	3.48e-05	0.00058	CcSEcCtD
Vandetanib—Abdominal pain—Docetaxel—skin cancer	3.36e-05	0.00056	CcSEcCtD
Vandetanib—Body temperature increased—Docetaxel—skin cancer	3.36e-05	0.00056	CcSEcCtD
Vandetanib—Asthenia—Docetaxel—skin cancer	3.05e-05	0.000509	CcSEcCtD
Vandetanib—Pruritus—Docetaxel—skin cancer	3.01e-05	0.000502	CcSEcCtD
Vandetanib—Diarrhoea—Docetaxel—skin cancer	2.91e-05	0.000485	CcSEcCtD
Vandetanib—Dizziness—Docetaxel—skin cancer	2.81e-05	0.000469	CcSEcCtD
Vandetanib—Vomiting—Docetaxel—skin cancer	2.71e-05	0.000451	CcSEcCtD
Vandetanib—Rash—Docetaxel—skin cancer	2.68e-05	0.000447	CcSEcCtD
Vandetanib—Dermatitis—Docetaxel—skin cancer	2.68e-05	0.000447	CcSEcCtD
Vandetanib—Headache—Docetaxel—skin cancer	2.67e-05	0.000444	CcSEcCtD
Vandetanib—Nausea—Docetaxel—skin cancer	2.53e-05	0.000421	CcSEcCtD
Vandetanib—EGFR—Innate Immune System—NRAS—skin cancer	3.28e-06	5.94e-05	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—TP53—skin cancer	3.27e-06	5.94e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—KRAS—skin cancer	3.26e-06	5.92e-05	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—TP53—skin cancer	3.26e-06	5.91e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—KRAS—skin cancer	3.25e-06	5.9e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—BRAF—skin cancer	3.24e-06	5.89e-05	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—HRAS—skin cancer	3.24e-06	5.89e-05	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—TP53—skin cancer	3.22e-06	5.85e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—ERCC2—skin cancer	3.22e-06	5.84e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—KRAS—skin cancer	3.22e-06	5.84e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—KRAS—skin cancer	3.22e-06	5.84e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—KRAS—skin cancer	3.21e-06	5.82e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—BRAF—skin cancer	3.2e-06	5.81e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—KRAS—skin cancer	3.19e-06	5.79e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—HRAS—skin cancer	3.19e-06	5.79e-05	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—KRAS—skin cancer	3.18e-06	5.78e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—HRAS—skin cancer	3.18e-06	5.76e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FOXO4—skin cancer	3.17e-06	5.74e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—NRAS—skin cancer	3.16e-06	5.74e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—NRAS—skin cancer	3.16e-06	5.74e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—IL6—skin cancer	3.16e-06	5.73e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—NRAS—skin cancer	3.16e-06	5.73e-05	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—NRAS—skin cancer	3.15e-06	5.71e-05	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—HRAS—skin cancer	3.14e-06	5.71e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—HRAS—skin cancer	3.14e-06	5.7e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—ENO2—skin cancer	3.14e-06	5.69e-05	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—KRAS—skin cancer	3.13e-06	5.69e-05	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—HRAS—skin cancer	3.13e-06	5.68e-05	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—HRAS—skin cancer	3.11e-06	5.65e-05	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—IL6—skin cancer	3.1e-06	5.63e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—NRAS—skin cancer	3.1e-06	5.63e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—BRAF—skin cancer	3.09e-06	5.62e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PLIN2—skin cancer	3.09e-06	5.61e-05	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—HRAS—skin cancer	3.08e-06	5.59e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—IL6—skin cancer	3.05e-06	5.54e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—IL6—skin cancer	3.04e-06	5.51e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—NRAS—skin cancer	3.03e-06	5.5e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—TERT—skin cancer	3.02e-06	5.48e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—KRAS—skin cancer	3.02e-06	5.48e-05	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—IL6—skin cancer	3.01e-06	5.46e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—NRAS—skin cancer	3.01e-06	5.46e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—IL6—skin cancer	3.01e-06	5.45e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TERT—skin cancer	2.98e-06	5.4e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—BRAF—skin cancer	2.97e-06	5.4e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—ERCC2—skin cancer	2.95e-06	5.36e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—KRAS—skin cancer	2.95e-06	5.35e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TERT—skin cancer	2.91e-06	5.29e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—HRAS—skin cancer	2.88e-06	5.22e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TERT—skin cancer	2.87e-06	5.21e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—TP53—skin cancer	2.86e-06	5.19e-05	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—HRAS—skin cancer	2.84e-06	5.16e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—KRAS—skin cancer	2.82e-06	5.12e-05	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—HRAS—skin cancer	2.82e-06	5.11e-05	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—HRAS—skin cancer	2.8e-06	5.09e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—BRAF—skin cancer	2.8e-06	5.09e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—NRAS—skin cancer	2.79e-06	5.07e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—HRAS—skin cancer	2.77e-06	5.03e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—HRAS—skin cancer	2.76e-06	5.01e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—IL6—skin cancer	2.75e-06	5e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—HRAS—skin cancer	2.74e-06	4.96e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—HRAS—skin cancer	2.74e-06	4.96e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—HRAS—skin cancer	2.73e-06	4.95e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—KRAS—skin cancer	2.72e-06	4.94e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—KRAS—skin cancer	2.72e-06	4.94e-05	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—IL6—skin cancer	2.72e-06	4.94e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—PTGS2—skin cancer	2.72e-06	4.93e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—KRAS—skin cancer	2.72e-06	4.93e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—HRAS—skin cancer	2.71e-06	4.92e-05	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—KRAS—skin cancer	2.71e-06	4.91e-05	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—HRAS—skin cancer	2.71e-06	4.91e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—BRAF—skin cancer	2.7e-06	4.9e-05	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—IL6—skin cancer	2.7e-06	4.89e-05	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—IL6—skin cancer	2.68e-06	4.87e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—NRAS—skin cancer	2.68e-06	4.87e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—TP53—skin cancer	2.68e-06	4.87e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—KRAS—skin cancer	2.67e-06	4.85e-05	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—HRAS—skin cancer	2.66e-06	4.83e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—IL6—skin cancer	2.65e-06	4.82e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—PTGS2—skin cancer	2.62e-06	4.75e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—IL6—skin cancer	2.62e-06	4.75e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—IL6—skin cancer	2.62e-06	4.75e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—IL6—skin cancer	2.61e-06	4.73e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—KRAS—skin cancer	2.61e-06	4.73e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—IL6—skin cancer	2.6e-06	4.71e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—KRAS—skin cancer	2.59e-06	4.7e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—HRAS—skin cancer	2.57e-06	4.65e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—NRAS—skin cancer	2.51e-06	4.56e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—HRAS—skin cancer	2.51e-06	4.55e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CSPG4—skin cancer	2.49e-06	4.52e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TERT—skin cancer	2.48e-06	4.5e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.45e-06	4.45e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—KRAS—skin cancer	2.41e-06	4.36e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PTGS2—skin cancer	2.4e-06	4.36e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—IL6—skin cancer	2.4e-06	4.35e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—HRAS—skin cancer	2.4e-06	4.35e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—BRAF—skin cancer	2.39e-06	4.34e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TERT—skin cancer	2.39e-06	4.33e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—TP53—skin cancer	2.37e-06	4.31e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—BRAF—skin cancer	2.36e-06	4.28e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—HRAS—skin cancer	2.31e-06	4.2e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—HRAS—skin cancer	2.31e-06	4.2e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—KRAS—skin cancer	2.31e-06	4.19e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—HRAS—skin cancer	2.31e-06	4.19e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—BRAF—skin cancer	2.31e-06	4.19e-05	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—HRAS—skin cancer	2.3e-06	4.18e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—NRAS—skin cancer	2.3e-06	4.17e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—IL6—skin cancer	2.29e-06	4.16e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—NRAS—skin cancer	2.29e-06	4.16e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—BRAF—skin cancer	2.27e-06	4.12e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—HRAS—skin cancer	2.27e-06	4.12e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—PTGS2—skin cancer	2.26e-06	4.11e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—NRAS—skin cancer	2.24e-06	4.07e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—NRAS—skin cancer	2.24e-06	4.06e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—NRAS—skin cancer	2.23e-06	4.05e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—HRAS—skin cancer	2.22e-06	4.02e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—NRAS—skin cancer	2.22e-06	4.02e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—IL6—skin cancer	2.22e-06	4.02e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—IL6—skin cancer	2.22e-06	4.02e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—IL6—skin cancer	2.21e-06	4.01e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—NRAS—skin cancer	2.21e-06	4.01e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—HRAS—skin cancer	2.2e-06	3.99e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—PTGS2—skin cancer	2.18e-06	3.96e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—KRAS—skin cancer	2.16e-06	3.92e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—NRAS—skin cancer	2.12e-06	3.84e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TERT—skin cancer	2.11e-06	3.84e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—IL6—skin cancer	2.11e-06	3.82e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—NRAS—skin cancer	2.1e-06	3.8e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—NRAS—skin cancer	2.09e-06	3.79e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—HRAS—skin cancer	2.04e-06	3.71e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—NRAS—skin cancer	2.04e-06	3.7e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—NRAS—skin cancer	2.01e-06	3.65e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTGS2—skin cancer	2.01e-06	3.65e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—KRAS—skin cancer	1.98e-06	3.59e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—KRAS—skin cancer	1.97e-06	3.58e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—HRAS—skin cancer	1.96e-06	3.56e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—BRAF—skin cancer	1.96e-06	3.56e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—IL6—skin cancer	1.96e-06	3.55e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—NRAS—skin cancer	1.94e-06	3.53e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PTGS2—skin cancer	1.93e-06	3.5e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—KRAS—skin cancer	1.93e-06	3.5e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—KRAS—skin cancer	1.93e-06	3.5e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TP53—skin cancer	1.92e-06	3.49e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—KRAS—skin cancer	1.92e-06	3.49e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—NRAS—skin cancer	1.91e-06	3.46e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—KRAS—skin cancer	1.91e-06	3.46e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—KRAS—skin cancer	1.9e-06	3.45e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—BRAF—skin cancer	1.89e-06	3.43e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—NRAS—skin cancer	1.87e-06	3.39e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—HRAS—skin cancer	1.84e-06	3.34e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—NRAS—skin cancer	1.84e-06	3.34e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—ERCC2—skin cancer	1.82e-06	3.31e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—KRAS—skin cancer	1.82e-06	3.3e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—KRAS—skin cancer	1.8e-06	3.27e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—KRAS—skin cancer	1.8e-06	3.26e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTGS2—skin cancer	1.77e-06	3.21e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—NRAS—skin cancer	1.76e-06	3.2e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—IL6—skin cancer	1.76e-06	3.19e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—skin cancer	1.76e-06	3.19e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—KRAS—skin cancer	1.75e-06	3.18e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—KRAS—skin cancer	1.73e-06	3.14e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—skin cancer	1.71e-06	3.11e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—NRAS—skin cancer	1.7e-06	3.08e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—skin cancer	1.69e-06	3.08e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ENO2—skin cancer	1.69e-06	3.07e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—HRAS—skin cancer	1.68e-06	3.05e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HRAS—skin cancer	1.68e-06	3.04e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—BRAF—skin cancer	1.67e-06	3.04e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—KRAS—skin cancer	1.67e-06	3.04e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—KRAS—skin cancer	1.64e-06	2.98e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—HRAS—skin cancer	1.64e-06	2.98e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—HRAS—skin cancer	1.64e-06	2.97e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HRAS—skin cancer	1.63e-06	2.96e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—NRAS—skin cancer	1.63e-06	2.95e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HRAS—skin cancer	1.62e-06	2.94e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—HRAS—skin cancer	1.62e-06	2.93e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL6—skin cancer	1.61e-06	2.92e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KRAS—skin cancer	1.61e-06	2.92e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL6—skin cancer	1.6e-06	2.91e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—skin cancer	1.6e-06	2.91e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—KRAS—skin cancer	1.58e-06	2.87e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL6—skin cancer	1.57e-06	2.85e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL6—skin cancer	1.57e-06	2.85e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL6—skin cancer	1.56e-06	2.84e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL6—skin cancer	1.55e-06	2.81e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—HRAS—skin cancer	1.55e-06	2.81e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL6—skin cancer	1.55e-06	2.81e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—skin cancer	1.54e-06	2.79e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—HRAS—skin cancer	1.53e-06	2.78e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HRAS—skin cancer	1.53e-06	2.77e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—KRAS—skin cancer	1.52e-06	2.75e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—NRAS—skin cancer	1.5e-06	2.73e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—HRAS—skin cancer	1.49e-06	2.71e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—skin cancer	1.49e-06	2.7e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NRAS—skin cancer	1.48e-06	2.69e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—IL6—skin cancer	1.48e-06	2.69e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HRAS—skin cancer	1.47e-06	2.67e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL6—skin cancer	1.46e-06	2.65e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—KRAS—skin cancer	1.46e-06	2.65e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NRAS—skin cancer	1.45e-06	2.63e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NRAS—skin cancer	1.43e-06	2.59e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—IL6—skin cancer	1.43e-06	2.59e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HRAS—skin cancer	1.42e-06	2.58e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL6—skin cancer	1.41e-06	2.56e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—KRAS—skin cancer	1.4e-06	2.54e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HRAS—skin cancer	1.4e-06	2.53e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HRAS—skin cancer	1.37e-06	2.48e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL6—skin cancer	1.36e-06	2.47e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—HRAS—skin cancer	1.35e-06	2.44e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL6—skin cancer	1.34e-06	2.42e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—IL6—skin cancer	1.31e-06	2.37e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—KRAS—skin cancer	1.29e-06	2.35e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—HRAS—skin cancer	1.29e-06	2.34e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL6—skin cancer	1.29e-06	2.34e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KRAS—skin cancer	1.27e-06	2.31e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KRAS—skin cancer	1.25e-06	2.26e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—HRAS—skin cancer	1.24e-06	2.25e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NRAS—skin cancer	1.23e-06	2.24e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—IL6—skin cancer	1.23e-06	2.24e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KRAS—skin cancer	1.23e-06	2.23e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—HRAS—skin cancer	1.19e-06	2.16e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NRAS—skin cancer	1.19e-06	2.16e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—IL6—skin cancer	1.19e-06	2.16e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL6—skin cancer	1.14e-06	2.07e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—skin cancer	1.13e-06	2.06e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—skin cancer	1.11e-06	2.01e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—HRAS—skin cancer	1.1e-06	1.99e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—skin cancer	1.09e-06	1.98e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—skin cancer	1.09e-06	1.98e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HRAS—skin cancer	1.08e-06	1.97e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KRAS—skin cancer	1.06e-06	1.93e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HRAS—skin cancer	1.06e-06	1.93e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NRAS—skin cancer	1.05e-06	1.91e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—IL6—skin cancer	1.05e-06	1.91e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HRAS—skin cancer	1.04e-06	1.9e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL6—skin cancer	1.04e-06	1.88e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KRAS—skin cancer	1.02e-06	1.86e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL6—skin cancer	1.02e-06	1.84e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL6—skin cancer	1e-06	1.81e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ERCC2—skin cancer	9.83e-07	1.78e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—skin cancer	9.44e-07	1.71e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—skin cancer	9.09e-07	1.65e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KRAS—skin cancer	9.06e-07	1.64e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HRAS—skin cancer	9.02e-07	1.64e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HRAS—skin cancer	8.7e-07	1.58e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6—skin cancer	8.64e-07	1.57e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6—skin cancer	8.32e-07	1.51e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—skin cancer	8.05e-07	1.46e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HRAS—skin cancer	7.7e-07	1.4e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6—skin cancer	7.37e-07	1.34e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—skin cancer	5.9e-07	1.07e-05	CbGpPWpGaD
